Cholangiocarcinoma

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

Retrieved on: 
Tuesday, October 24, 2023

The Company had previously announced the first patient in the head and neck squamous cell carcinoma cohort of the study had been treated.

Key Points: 
  • The Company had previously announced the first patient in the head and neck squamous cell carcinoma cohort of the study had been treated.
  • The BOLSTER trial is a basket trial being conducted at approximately 40 sites in North America, Europe, and Asia-Pacific.
  • Total trial enrollment of 120 patients is expected to be completed in the second half of 2024.
  • “We are excited to announce treatment of the first patient in the cholangiocarcinoma cohort of the BOLSTER trial.

Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Retrieved on: 
Monday, October 23, 2023

BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.

Key Points: 
  • BDC-1001 comprises a HER2-targeting biosimilar of trastuzumab conjugated with a non-cleavable linker to a proprietary TLR7/8 agonist.
  • The Phase 1 dose-escalation trial enrolled 131 patients with 16 different HER2-expressing solid tumor types across 18 dose levels in two arms, monotherapy and in combination with nivolumab.
  • The response rate at the RP2D was 29% in evaluable patients with HER2-positive tumors, both in monotherapy (2/7, 29%) and in combination with nivolumab (2/7, 29%).
  • Additionally, a copy of the presentation is available on the Publications page of the Bolt Therapeutics website.

Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting

Retrieved on: 
Thursday, October 19, 2023

Foundation Medicine, Inc ., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.

Key Points: 
  • Foundation Medicine, Inc ., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.
  • In patients with CUP, the tumor of origin is unknown, which has historically made targeted treatment challenging.
  • As a result, there has been little progress in improving the poor outcomes for these patients.
  • Follow Foundation Medicine on Twitter and LinkedIn for more updates from #ESMO23 and visit us in person at Booths 727 and 728.

Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors

Retrieved on: 
Thursday, October 12, 2023

ET

Key Points: 
  • ET
    BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced initial clinical data for RLY-4008 (lirafugratinib) in patients with FGFR2-altered solid tumors.
  • The data demonstrate activity across several sub-groups, including patients with FGFR2-fusion tumors and patients with FGFR2-altered HR+/HER2- breast cancer.
  • These data are being presented today at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
  • Registration and dial-in for the conference call may be accessed on Relay Therapeutics’ website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations .

Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil

Retrieved on: 
Tuesday, October 10, 2023

Marketing authorization applications for pemigatinib have also been submitted previously in Colombia, Mexico and Argentina.

Key Points: 
  • Marketing authorization applications for pemigatinib have also been submitted previously in Colombia, Mexico and Argentina.
  • This kind of tumor is considered rare, and more than 50% of the patients are diagnosed in advanced disease stages.
  • Upon obtaining the marketing authorization from ANVISA, Knight submitted an application for pricing approval to the Drugs Market Regulation Chamber (“CMED”) which establishes maximum prices allowed for drugs sold in Brazil.
  • Knight has also submitted marketing authorization applications for tafasitamab in Colombia, Mexico and Argentina.

New Study Demonstrates Lunit SCOPE IO's Effectiveness to Predict Biliary Tract Cancer Therapy Outcomes - Findings to be Presented at the ESMO 2023

Retrieved on: 
Monday, October 16, 2023

SEOUL, South Korea, Oct. 16, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 9 studies at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, to be held in Madrid, Spain, from October 20-24.

Key Points: 
  • A collaborative study indicated that AI-based immune phenotyping can predict therapy outcomes in advanced biliary tract cancer (BTC) patients who are planning to be treated with anti-PD-1 therapy.
  • In the study, the research team defined the immune phenotype of the WSI samples via Lunit SCOPE IO, Lunit's AI TIL (tumor-infiltrating lymphocytes) analyzer.
  • In another study, HER2 (human epidermal growth factor receptor-2) scoring in biliary tract cancer was evaluated using Lunit SCOPE HER2.
  • Another study aimed to predict multiple druggable mutations in non-small cell lung cancer (NSCLC) based on AI analysis of H&E images.

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

Retrieved on: 
Sunday, October 8, 2023

The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.

Key Points: 
  • The transaction was unanimously approved by both the Bristol Myers Squibb and the Mirati Boards of Directors.
  • Mirati’s assets are a strong fit with Bristol Myers Squibb’s portfolio and innovative pipeline and represent an attractive opportunity to grow Bristol Myers Squibb’s oncology franchise.
  • Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio.
  • Bristol Myers Squibb expects to finance the acquisition with a combination of cash and debt.

Lunit to Showcase 9 AI-based Research Results at ESMO 2023

Retrieved on: 
Tuesday, October 10, 2023

SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 9 studies featuring its AI pathology research at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, scheduled to be held in Madrid, Spain, from October 20 to October 24, 2023.

Key Points: 
  • The highlighted abstracts for ESMO 2023 include:
    Lunit investigates AI's potential to predict multiple druggable mutations in non-small cell lung cancer from H&E stained images, paving the way for more efficient clinical workflows and treatment decisions.
  • In another study utilizing Lunit SCOPE HER2, Lunit assesses HER2 expression and TIL (Tumor-infiltrating lymphocyte) density in biliary tract cancer, providing valuable insights into the tumor microenvironment's role in treatment strategies.
  • "These groundbreaking abstracts showcase the power of the Lunit SCOPE suite in unraveling complex insights across various cancer types, from distinguishing tumor subtypes to predicting treatment responses," said Brandon Suh, CEO of Lunit.
  • For inquiries or to schedule a meeting with the Lunit team, please contact [email protected] .

TransThera announces two oral presentations of tinengotinib clinical data at 2023 ESMO and SABCS annual meetings

Retrieved on: 
Monday, October 9, 2023

NANJING, China, Oct. 9, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announces to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at 2023 European Society for Medical Oncology (ESMO) Congress, and in breast cancer at 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting respectively.

Key Points: 
  • NANJING, China, Oct. 9, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announces to deliver two oral presentations of tinengotinib clinical data in cholangiocarcinoma (CCA) at 2023 European Society for Medical Oncology (ESMO) Congress, and in breast cancer at 2023 San Antonio Breast Cancer Symposium (SABCS) annual meeting respectively.
  • TransThera will also give a poster presentation of tinengotinib phase 1b/2 clinical data in Chinese patients at 2023 ESMO.
  • Title: Tinengotinib in Patients with Advanced, Fibroblast Growth Factor Receptor (FGFR) inhibitor Refractory/Relapsed Cholangiocarcinoma
    Title: Preliminary Efficacy and Safety of Tinengotinib (TT-00420) Monotherapy in Chinese Patients (pts) with Advanced Solid Tumors: Results from a Phase Ib/II Study
    "We are thrilled that tinengotinib clinical data has been selected for multiple oral and poster presentations in these impactful global scientific meetings. "
  • The upcoming presentations mark the potential of tinengotinib in CCA and breast cancer.

Relay Therapeutics to Present Clinical Data on RLY-4008 in Advanced FGFR2-Altered Solid Tumors at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, September 18, 2023

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023.
  • Details of the oral presentation are as follows:
    Title: Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study
    The conference website indicates that full abstracts will be available for registrants via the conference app on October 4, 2023, at 12:00 p.m.
  • Relay Therapeutics will host a conference call to discuss these data.
  • Details will be provided at a future date and available on our website under Events in the News & Events section through the following link: https://ir.relaytx.com/news-events/events-presentations .